000078 Shenzhen Neptunus Bioengineering
- 2.62
- +0.21+8.71%
Shenzhen Neptunus Bioengineering News
Haiwang Bio (000078): foreign Investment rating (FIR)
Sea King Bio (000078): 2019Q4 Foreign Investment rating report (overseas Institution Investment rating C)
Neptune Biotech (000078) interim report review: Continued performance is impressive, operating cash flow improved in Q2
Kaiwang Biotech (000078) Review of the Third Quarterly Report: Beautiful Performance and Strong M&A Execution
Deepin* Company* Haiwang Biotech (000078) Interim Report Comment: Accelerating Mergers and Acquisitions, Accelerating Expansion, Endogenous Outreach, Establishing a Rapid Growth Trend
Deep*Company*Kaiwang Biotech (000078) In-depth Research: Epitaxial Acceleration Achieves Leapfrog Development to Build a Regional Distribution Leader
Haiwang Bio (000078) comment report: the pharmaceutical business is expanding rapidly and many businesses are also being promoted.
[China Galaxy] Haiwang Biological Review report: pharmaceutical business is expanding rapidly, and a number of businesses are also being promoted.
Depth * Company * Sea King Biology (000078): continue to promote the growth of GPO procurement business performance without worry
[bank of China International Securities] Haiwang Bio: continue to promote GPO procurement business, worry-free performance growth
海王生物(000078)点评：流通、制造双核驱动下的医药巨头
【国信证券】海王生物:打造一致性评价平台,保障全药网持续推进
海王生物(000078)点评：打造一致性评价平台 保障全药网持续推进
【西南证券】海王生物:进军质子医疗,A股高精尖医疗设备稀缺标的
海王生物(000078)点评：进军质子医疗 A股高精尖医疗设备稀缺标的
海王生物(000078)调研简报：深圳GPO模式即将实施 海王为最佳收益标的
【西南证券】海王生物:深圳GPO模式即将实施,海王为最佳收益标的
海王生物(000078)季报点评：定增即将完成 业绩加速改善
【国信证券】海王生物:定增即将完成,业绩加速改善
海王生物(000078)年报点评：把握医改大机会 GPO延伸+外延驱动成长
Analysis
Price Target
No Data
No Data